臨床婦人科産科76巻3号

2022年04月発行

今月の臨床 がん遺伝子検査に基づく婦人科がん治療―最前線のレジメン選択法を理解する

治療薬

免疫チェックポイント阻害薬の位置づけ

著者： 濵西潤三¹ 山ノ井康二¹ 浮田真沙世¹ 滝真奈¹ 山口建¹ 万代昌紀¹

所属機関： ¹京都大学医学部婦人科学産科学教室

ページ範囲：P.373 - P.379

文献概要

●MSI-High婦人科がんに対して，ペムブロリズマブは有用である．

●がん遺伝子パネル検査と患者申出療養制度を利用した免疫チェックポイント阻害薬へのアクセスが可能となっている．

参考文献

1）Liu J, et al : PD-1/PD-L1 checkpoint inhibitors in tumor immunotherapy. Front Pharmacol 12 : 731798, 2021

2）Iwai Y, et al : Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci 24 : 26, 2017

3）Lawrence MS, et al : Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499 : 214-218, 2013

4）Le DT, et al : Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357 : 409-413, 2017

5）Marabelle A, et al : Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer : results from the phase II KEYNOTE-158 study. J Clin Oncol 38 : 1-10, 2020

6）Oaknin A, et al : Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer : a nonrandomized phase 1 clinical trial. JAMA Oncol 6 : 1766-1772, 2020

7）Konstantinopoulos PA, et al : Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent/persistent endometrial cancer. J Clin Oncol 37 : 2786-2794, 2019

8）Antil YC, et al : Activity of durvalumab in advanced endometrial cancer（AEC） according to mismatch repair（MMR）status : the phase II PHAEDRA trial（ANZGOG1601）2019 ASCO Annual Meeting Abstract 5501. J Clin Oncol 37（suppl） : 5501, 2019

9）Bellone S, et al : A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high（MSI-H）endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics（NCT02899793）. Ann Oncol 32 : 1045-1046, 2021

10）Makker V, et al : Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer : an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 20 : 711-718, 2019

11）Makker V, et al : Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol 38 : 2981-2992, 2020

12）Makker V, et al : A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in patients with advanced endometrial cancer. Society of Gynecologic Oncology 52nd Annual Meeting on Women's Cancer. Gynecol Oncol 162（suppl 1） : S4, 2021

13）Marabelle A, et al : Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab : prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 21 : 1353-1365, 2020

14）臨床研究実施計画・研究概要公開システム．遺伝子パネル検査による遺伝子プロファイリングに基づく複数の分子標的治療に関する患者申出療養（NCCH1901）．https://jrct.niph.go.jp/latest-detail/jRCTs031190104

15）国立がん研究センター中央病院 : 治療選択肢の可能性を求めて（患者申出療養）．遺伝子パネル検査による遺伝子プロファイリングに基づく複数の分子標的治療に関する患者申出療養について．https://www.ncc.go.jp/jp/ncch/genome/90/index.html

16）Rousseau B, et al : The spectrum of benefit from checkpoint blockade in hypermutated tumors. N Engl J Med 384 : 1168-1170, 2021

17）Cristescu R, et al : Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 362 : eaar3593, 2018

18）Murakami R, et al : Combination of gene set signatures correlates with response to nivolumab in platinum-resistant ovarian cancer. Sci Rep 11 : 11427, 2021

19）Tischkowitz M, et al : Small-cell carcinoma of the ovary, hypercalcemic type-genetics, new treatment targets, and current management guidelines. Clin Cancer Res 26 : 3908-3917, 2020

20）Jelinic P, et al : Immune-active microenvironment in small cell carcinoma of the ovary, hypercalcemic type : rationale for immune checkpoint blockade. J Natl Cancer Inst 110 : 787-790, 2018

21）Chung HC, et al : Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer : results from the phase II KEYNOTE-158 study. J Clin Oncol 37 : 1470-1478, 2019

22）Tewari KS, et al : EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 : interim analysis of phase III trial of cemiplimab vs. investigator's choice chemotherapy in recurrent/metastatic cervical carcinoma. ESMO Virtual Plenary. Abstract VP4-2021. Presented May 12, 2021

23）Goodman AM, et al : Prevalence of PDL1 amplification and preliminary response to immune checkpoint blockade in solid tumors. JAMA Oncol 4 : 1237-1244, 2018

24）Sidaway P : MSI-H : a truly agnostic biomarker? Nat Rev Clin Oncol 17 : 68, 2020